Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, as they have been shown to reduce t...
Main Authors: | Donatella Zodda, Rosario Giammona, Silvia Schifilliti |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-01-01
|
Series: | Pharmacy |
Subjects: | |
Online Access: | http://www.mdpi.com/2226-4787/6/1/10 |
Similar Items
-
Assessment of the global and national market for lipid modifying agents: retrospective and innovation
by: A. V. Lokhmacheva, et al.
Published: (2023-08-01) -
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
by: Yoonkyung Chang, et al.
Published: (2023-04-01) -
Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence
by: Keshav Kumar Gupta, et al.
Published: (2018-12-01) -
Effects of Hypolipidemic Drugs on Psoriasis
by: Mateusz Matwiejuk, et al.
Published: (2023-03-01) -
New Drugs for Treating Dyslipidemia: Beyond Statins
by: Chang Ho Ahn, et al.
Published: (2015-04-01)